AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens  1     Remo Panaccione  2     Julian Panés  3     William Sandborn  4     Brian G. Feagan  5     Tadakazu Hisamatsu  6     Peter Bossuyt  7     Marc Ferrante  8     Silvio Danese  9     Ezequiel Neimark  10     Alexandra Song  10     Xiaomei Liao  10     Tian Feng  10     Rachel Duan  10     Sofie Berg  10     Kori Wallace  10     Jean-Frédéric Colombel  11    
1 Amsterdam University Medical Center, Amsterdam, Netherlands
2 University of Calgary, Calgary, Canada
3 Hospital Clínic Barcelona, Barcelona, Spain
4 University of California San Diego, San Diego, United States
5 Alimentiv Inc., London, Canada
6 Kyorin University School of Medicine, Tokyo, Japan
7 Imelda General Hospital, Bonheiden, Belgium
8 University Hospitals Leuven, Leuven, Belgium
9 IRCCS Humanitas Research Hospital and Hunimed, Rozzano, Italy
10 AbbVie Inc., North Chicago, United States
11 Icahn School of Medicine at Mount Sinai, USA, United States

Topic
IBD, Immunology

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing